12基因进展评分在非肌层浸润性膀胱癌中的预后影响:一项前瞻性多中心验证研究
该研究在10个欧洲中心前瞻性纳入1224例非肌层浸润性膀胱癌患者,其中750例(851个肿瘤)符合纳入和样本质量标准,随访平均28个月。12基因进展评分与疾病进展显著相关(p<0.001),多变量Cox回归显示其提供独立于临床和病理危险因素的预后信息(p<0.001),一致性统计量从0.82升至0.86。
要点
- 分子高风险患者疾病进展更频繁(HR 5.08,95%CI 2.2-11.6;p<0.001)。
- 进展评分提供独立于临床和病理危险因素的预后信息(p<0.001)。
- 进展评分在新鲜冷冻与福尔马林固定石蜡包埋肿瘤标本间高度相关(R²=0.85)。
核心结论
- 12基因进展评分具有超越临床和病理危险因素的独立预后能力,可能有助于对非肌层浸润性膀胱癌患者进行分层以优化治疗和随访方案。
研究设计与样本
- 前瞻性多中心验证研究,2008年至2012年间在10个欧洲中心纳入1224例患者,其中750例患者(851个肿瘤)符合纳入和样本质量标准,随访平均28个月(范围0-76个月)。
主要发现
- 进展评分与年龄、分期、分级、原位癌、卡介苗治疗、欧洲癌症研究与治疗组织风险评分及疾病进展显著相关(p<0.001)。
- 单变量Cox回归分析显示,分子分类为高风险的患者疾病进展更频繁(HR 5.08,95%CI 2.2-11.6;p<0.001)。
- 多变量Cox回归模型显示,进展评分提供独立于临床和组织病理学危险因素的预后信息(p<0.001),一致性统计量从0.82增加至0.86。
- 进展评分在配对的新鲜冷冻与福尔马林固定石蜡包埋肿瘤标本间显示高度相关性(R²=0.85)。
关键数值与推荐
- 进展评分采用预定义公式和截断值计算。
- 分子高风险患者疾病进展的HR为5.08(95%CI 2.2-11.6;p<0.001)。
- 多变量模型中进展评分的p<0.001,一致性统计量从0.82升至0.86。
- 配对标本间进展评分的R²=0.85。
临床怎么用
- 作者认为,12基因分子检测的临床使用可能有助于对非肌层浸润性膀胱癌患者进行分层以选择最佳治疗方案。
局限性
- 进展率相对较低(5%,37/750例患者)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Progression of non-muscle-invasive bladder cancer (NMIBC) to muscle-invasive bladder cancer (MIBC) is life-threatening and cannot be accurately predicted using clinical and pathological risk factors. Biomarkers for stratifying patients to treatment and surveillance are greatly needed. OBJECTIVE: To validate a previously developed 12-gene progression score to predict progression to MIBC in a large, multicentre, prospective study. DESIGN, SETTING, AND PARTICIPANTS: We enrolled 1224 patients in ten European centres between 2008 and 2012. A total of 750 patients (851 tumours) fulfilled the inclusion and sample quality criteria for testing. Patients were followed for an average of 28 mo (range 0-76). A 12-gene real-time qualitative polymerase chain reaction assay was performed for all tumours and progression scores were calculated using a predefined formula and cut-off values. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We measured progression to MIBC using Cox regression analysis and log-rank tests for comparing survival distributions. RESULTS AND LIMITATIONS: The progression score was significantly (p<0.001) associated with age, stage, grade, carcinoma in situ, bacillus Calmette-Guérin treatment, European Organisation for Research and Treatment of Cancer risk score, and disease progression. Univariate Cox regression analysis showed that patients molecularly classified as high risk experienced more frequent disease progression (hazard ratio 5.08, 95% confidence interval 2.2-11.6; p<0.001). Multivariable Cox regression models showed that the progression score added independent prognostic information beyond clinical and histopathological risk factors (p<0.001), with an increase in concordance statistic from 0.82 to 0.86. The progression score showed high correlation (R2=0.85) between paired fresh-frozen and formalin-fixed paraffin-embedded tumour specimens, supporting translation potential in the standard clinical setting. A limitation was the relatively low progression rate (5%, 37/750 patients). CONCLUSIONS: The 12-gene progression score had independent prognostic power beyond clinical and histopathological risk factors, and may help in stratifying NMIBC patients to optimise treatment and follow-up regimens. PATIENT SUMMARY: Clinical use of a 12-gene molecular test for disease aggressiveness may help in stratifying patients with non-muscle-invasive bladder cancer to optimal treatment regimens.
引用
- Dyrskjøt L, Reinert T, Algaba F, et al. Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study. Eur Urol. 2017. PMID: 28583312. doi:10.1016/j.eururo.2017.05.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。